Status:
COMPLETED
14.0- 3.0- 3.0- η Protein With Rheumatoid Arthritis
Lead Sponsor:
Mansoura University
Conditions:
Disease Activity
Eligibility:
All Genders
18-70 years
Brief Summary
Aim of work: to explore the potential association between serum 14.0-3.0-3.0- η protein level with disease activity and bone mineral density (BMD) in Egyptian patients with rheumatoid arthritis (RA). ...
Detailed Description
A total of 200 RA patients were invited to be enrolled in this study. Patients were diagnosed as having RA by the 2010 European-league-against-Rheumatism- (EULAR) and American-College-of-rheumatology ...
Eligibility Criteria
Inclusion
- Patients were diagnosed as having RA by the 2010 European-league-against-Rheumatism- (EULAR) and American-College-of-rheumatology (ACR) classification criteria for RA Patients were collected from the outpatient clinic of the Rheumatology and Rehabilitation Department, Mansoura University Hospital
Exclusion
- postmenopausal females, patients with other rheumatic autoimmune diseases, severe infection, diabetes mellitus, hypertension, liver or kidney disease, malignancies, endocrinal diseases, pregnant or lactating females. Patients with current intake of glucocorticoids, anticonvulsants, estrogen or anti-coagulant, alcohol users, or other factors that lead to secondary osteoporosis were also excluded from the study
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 10 2022
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT05366608
Start Date
January 1 2019
End Date
March 10 2022
Last Update
May 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University
Al Mansurah, DK, Egypt, 35516